Chest Medicine
Reducing Risks from Coronavirus Transmission in the Home—The Role of Viral Load
7 May, 2020 | 09:01h | UTCReducing risks from coronavirus transmission in the home—the role of viral load – The BMJ
Commentaries: Can we do more to protect people at home when a family member has coronavirus? – University of Bristol AND Coronavirus: Exposure to higher ‘viral load’ when infected could make victims more severely ill – Yahoo News
Opinion – Awake Proning for COVID-19
6 May, 2020 | 03:53h | UTCAwake Proning for COVID-19 – PulmCrit
Tests in Recovered Patients Found to be False Positives, Not Reinfections
6 May, 2020 | 03:48h | UTCTests in recovered patients found false positives, not reinfections, experts say – The Korea Herald
See also: Recovered patients who tested positive for COVID-19 likely not reinfected – Live Science AND South Korea says recovered coronavirus patients who tested positive again did not relapse: Tests picked up ‘dead virus fragments’ – Business Insider
Systematic Review: Chloroquine and Hydroxychloroquine as a Treatment for COVID‐19
6 May, 2020 | 03:44h | UTC“Pending further results from more extensive studies with more stringent study parameters, clinicians should defer from routine use of HCQ and CQ.”
Despite Anticoagulation, Patients with Severe SARS-CoV-2 Infection are at Increased Risk of Developing Thrombosis
6 May, 2020 | 03:40h | UTC
Proposal for a COVID-19 Imaging Reporting and Data System (COVID-RADS)
5 May, 2020 | 04:46h | UTC
Cohort Study: Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19
3 May, 2020 | 22:25h | UTCCommentary: PulmCrit – Is COVID-19 ARDS, pseudoARDS, L, or H? Physiology data from Boston – PulmCrit
Related Commentary on Twitter
COVID-19 patients do not fall into distinct "phenotypes" of high and low compliance. They exhibit a continuum of compliance, mostly low, and entirely consistent with non-COVID ARDS cohorts.
https://t.co/KiHjWvIjX3 pic.twitter.com/g7FuhrlL49
— Robert Dickson (@robertpdickson) April 30, 2020
Short Review: Coagulopathy Associated with COVID-19
3 May, 2020 | 22:09h | UTCCoagulopathy associated with COVID-19 – Canadian Medical Association Journal
FDA Issues Emergency Use Authorization for the Use of Remdesivir to Treat COVID-19
3 May, 2020 | 22:03h | UTCSee also: Remdesivir: A Non-Antiviral Antiviral Drug? – Forbes
CO-RADS – A Categorical CT Assessment Scheme for Patients with Suspected COVID-19
1 May, 2020 | 03:48h | UTC
Study: Within 19 Days After Symptom Onset, 100% of Patients Test Positive for IGG
1 May, 2020 | 03:33h | UTCAntibody responses to SARS-CoV-2 in patients with COVID-19 – Nature Medicine
Commentary: Expert reaction to antibody response in COVID-19 patients – Science Media Centre
Small Observational Study Suggests Prophylactic LMWH Can Prevent COVID‐19 Disseminated Intravascular Coagulopathy
1 May, 2020 | 03:26h | UTCCOVID‐19 Coagulopathy in Caucasian patients – British Journal of Haematology
Treatment Considerations for COVID-19: A Critical Review of the Evidence
1 May, 2020 | 03:20h | UTC
Perspective: Urging Caution on Remdesivir
1 May, 2020 | 03:07h | UTCUrging Caution On Remdesivir – Forbes
Related: About Remdesivir and About “Game-Changers” – Science Translational Medicine AND Conflicting Remdesivir Trial Results Released; Experts Urge More Research – Health Policy Watch AND Is remdesivir a miracle drug to cure coronavirus? Don’t get your hopes up yet – The Conversation AND PulmCrit- First placebo-controlled RCT on remdesivir for COVID-19 – PulmCrit AND Remdesivir: the antiviral drug is being touted as a possible coronavirus treatment – but will it work? – The Guardian
“While I have enormous respect for the Institutes and their leaders, releasing the preliminary news without sharing the data behind it is highly irresponsible.”
Clinical Determinants for Fatality of 44,672 Patients with COVID-19
1 May, 2020 | 02:48h | UTCClinical determinants for fatality of 44,672 patients with COVID-19 – Critical Care
Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
30 Apr, 2020 | 04:31h | UTCCommentaries: First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed – The Lancet AND Expert reaction to trial of remdesivir in adults – Science Media Centre
See also: [Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
Related Commentary on Twitter
With all the hype about Remdesivir today @TheLancet has decided to lift the embargo and release this placebo-controlled multicenter study done in China that showed no benefit https://t.co/ZdmKfnWLyw
— Carlos del Rio (@CarlosdelRio7) April 29, 2020
[Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
30 Apr, 2020 | 04:28h | UTCCommentaries: Hopes rise on coronavirus drug remdesivir – Nature AND The COVID-19 research news rollercoaster is running again: STAT News + Gilead’s remdesivir – HealthNews Review
See also: Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
COVID-19 and Its Implications for Thrombosis and Anticoagulation
30 Apr, 2020 | 04:13h | UTCCOVID-19 and its implications for thrombosis and anticoagulation – Blood
Perspective: What Policy Makers Need to Know About COVID-19 Protective Immunity
29 Apr, 2020 | 05:19h | UTCWhat policy makers need to know about COVID-19 protective immunity – The Lancet
Related: What Covid-19 antibody tests say — and don’t say — about immunity – Vox AND The False Hope of Antibody Tests – The Atlantic AND What Antibody Studies Can Tell You — and More Importantly, What They Can’t – ProPublica AND What if immunity to covid-19 doesn’t last? – MIT Technology Review AND Beware of Antibody-based COVID-19 “Immunity Passports” – Scientific American AND Coronavirus immunity: Can you catch it twice? – BBC
Related Commentary on Twitter
An especially astute and succinct essay on #COVID19 protective immunity @TheLancet todayhttps://t.co/HFGUGPdson
highlights unknowns on duration, role of T lymphocytes, what constitutes real protection, and herd immunity features pic.twitter.com/oBC48DcGCl— Eric Topol (@EricTopol) April 28, 2020
Case Series: Characterization of Ischemic Cutaneous Lesions Associated with Covid-19
29 Apr, 2020 | 05:14h | UTCSee also: Journal articles on coronavirus with relevance for skin diseases and dermatology – Centre of Evidence Based Dermatology, University of Nottingham AND From ‘COVID Toes’ to Hives, These Are the Skin Conditions Dermatologists Think Could Be Signs of Coronavirus – TIME
Lung Pathology of COVID-19: Is AFOP in Play?
29 Apr, 2020 | 04:58h | UTCLung pathology of COVID-19: is AFOP in play? – PulmCrit
Why Don’t Some Coronavirus Patients Sense their Alarmingly Low Oxygen Levels?
29 Apr, 2020 | 05:11h | UTCWhy don’t some coronavirus patients sense their alarmingly low oxygen levels? – Science
Patients with Cancer More Vulnerable to SARS-COV-2
29 Apr, 2020 | 05:00h | UTCCommentaries: COVID-19 Increases Overall Risk of Death, Complications in Patients With Cancer, Study Shows – AJMC AND Patients with blood and lung cancers are three times more at risk of dying of coronavirus than people with other tumors, study finds – Daily Mail AND Coronavirus: Cancer patients nearly three times more likely to die of Covid-19, study says – Independent
BTS Guideline for the Use of Long-term Macrolides in Adults with Respiratory Disease
29 Apr, 2020 | 04:49h | UTC
Systematic Review: Antidepressants for Smoking Cessation
29 Apr, 2020 | 04:40h | UTCAntidepressants for smoking cessation – Cochrane Library
Summary: Do medicines used to treat depression help people to quit smoking? – Cochrane Library